Description: Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Home Page: www.revmed.com
RVMD Technical Analysis
700 Saginaw Drive
Redwood City,
CA
94063
United States
Phone:
650 481 6801
Officers
| Name | Title |
|---|---|
| Dr. Mark A. Goldsmith Ph.D. | CEO, Pres & Chairman |
| Mr. Jack Anders | Chief Financial Officer |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Pres of R&D |
| Ms. Xiaolin Wang | Exec. VP of Clinical Devel. |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Mr. David L. Pompliano Ph.D. | Founding Chief Scientific Officer |
| Mr. Walter Reiher Ph.D. | Chief Information Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1624 |
| Price-to-Sales TTM: | 72.2422 |
| IPO Date: | 2020-02-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 239 |